Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 13/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136791 | 0.78 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL6136630 | 0.78 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL6136929 | 0.78 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL5988800 | 0.70 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6137390 | 0.69 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6136734 | 0.68 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6136773 | 0.68 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6137099 | 0.67 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6136837 | 0.65 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL6136766 | 0.65 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1120409-B1 | 2,3-DISUBSTITUTED PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, DRUG COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6765095-B2 | HETEROCYCLIC IMINES SUCH AS 2-PHENOXY-3-(3-(PYRIDIN-4-YL)-PROPOXY)PYRIDINE, FORMED BY ETHERIFICATION, AMINATION OR SULIFIDING, FOR USE AS PHOSPHODIESTERASE INHIBITORS | DAINIPPON PHARMACEUTICAL COMPANY, LIMITED (JP) | 2004-07-20 | — | — | US | disclosed |
| US-6683186-B2 | CONDENSATION, ETHERIFICATION; PHOSPHODIESTERASE INHIBITORS; ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIASTHMATIC AGENTS | DAINIPPON PHARMACEUTICAL COMPANY, LIMITED (JP) | 2004-01-27 | — | — | US | disclosed |
| US-20030199554-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | KAWASAKI MOTOJI (JP) | 2003-10-23 | — | — | US | disclosed |
| US-20030195232-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | KAWASAKI MOTOJI (JP) | 2003-10-16 | — | — | US | disclosed |
| US-6555557-B1 | 2-(3-chlorophenoxy)-3-(3-(3-hydroxypyridin-5-yl)propoxy) -pyridine, for example; phosphodiesterase IV inhibitors | DAINIPPON PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1120409-A1 | 2,3-DISUBSTITUTED PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, DRUG COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION | Dainippon Pharmaceutical Co., Ltd. (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199554-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | NOX1, CYP4A11, PDE12 | PDE4A 16/4885PDE4B 13/4885PDE4C 52/4885 |
| US-20030195232-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | NOX1, CYP4A11, PDE12 | PDE4A 16/4885PDE4B 13/4885PDE4C 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.